Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - CRISPR Therapeutics AG | crsp-ex312_1004.htm |
| EX-32.1 - EX-32.1 - CRISPR Therapeutics AG | crsp-ex321_1003.htm |
| EX-31.1 - EX-31.1 - CRISPR Therapeutics AG | crsp-ex311_1005.htm |
| EX-23.2 - EX-23.2 - CRISPR Therapeutics AG | crsp-ex232_1000.htm |
| EX-21.1 - EX-21.1 - CRISPR Therapeutics AG | crsp-ex211_1002.htm |
| 10-K - 10-K - CRISPR Therapeutics AG | crsp-10k_20161231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-214184) pertaining to the CRISPR Therapeutics AG 2015 Stock Option and Grant Plan, the CRISPR Therapeutics AG 2016 Stock Option and Incentive Plan, the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan, the Non-Qualified Option Agreement with Megan Menner, the Non-Qualified Option Agreement with Paul Schneider, and the Non-Qualified Option Agreement with Pablo Cagnoni of CRISPR Therapeutics AG of our report dated March 10, 2017, with respect to the consolidated financial statements of CRISPR Therapeutics AG included in this Annual Report (Form 10-K) for the year ended December 31, 2016.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 10, 2017